Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma

Purpose: To assess the effectiveness and safety of adjunctive topical netarsudil 0.02% and latanoprostene bunod 0.024% in patients with glaucoma. Methods: A retrospective, multi-center, cohort study of patients with glaucoma treated with netarsudil 0.02% or latanoprostene bunod from five tertiary ca...

Full description

Saved in:
Bibliographic Details
Published in:European journal of ophthalmology 2022-01, Vol.32 (1), p.322-326
Main Authors: Mehta, Amy A, Kanu, Levi N, Sood-Mendiratta, Shalini, Quinones, Richard, Hawkins, Anjali, Lehrer, Richard A, Malhotra, Kiran, Papas, Robert, Hillman, David, Wilensky, Jacob T, Aref, Ahmad A, Vajaranant, Thasarat Sutabutr, Edward, Deepak P
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: To assess the effectiveness and safety of adjunctive topical netarsudil 0.02% and latanoprostene bunod 0.024% in patients with glaucoma. Methods: A retrospective, multi-center, cohort study of patients with glaucoma treated with netarsudil 0.02% or latanoprostene bunod from five tertiary care centers. Inclusion criteria included patients with glaucoma treated with either medication as adjunctive therapy. Outcomes included mean absolute intraocular pressure (IOP) reduction and relative IOP reduction from baseline. Adverse reactions and reasons for discontinuation were reported. One-way analysis of variance, Kruskal-Wallis rank sum test, and Mann Whitney U test compared the outcomes. Results: A total of 95 eyes (95 patients) on netarsudil and 41 eyes (41 patients) on latanoprostene bunod were analyzed. Mean duration of use was 54.3 ± 28 days for netarsudil and 82.9 ± 51.2 days for latanoprostene bunod. At the final visit, mean IOP reduction was 3.9 ± 4.6 mmHg (17.5 ± 6.0%) (p 
ISSN:1120-6721
1724-6016
DOI:10.1177/1120672121998913